SCHEMBL167148

SCHEMBL167148

CCCCc1cc(C(=O)OC)cc(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)c(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8013021 0.92
SCHEMBL8007311 0.91
SCHEMBL8007854 0.91 AGTR1 (0.37)
SCHEMBL8007768 0.91
SCHEMBL7998174 0.90
SCHEMBL8434189 0.89
Potassium SCHEMBL8911660 0.89
Embusartan SCHEMBL5537214 0.89
SCHEMBL8894371 0.89
SCHEMBL8009771 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082608-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE SINGAPORE HEALTH SERVICES PTE LTD. (SG) 2025-03-13 US claimed
EP-4448096-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE Singapore Health Services Pte. Ltd. (SG) 2024-10-23 EP claimed
US-12064429-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use ADVERIO PHARMA GMBH (DE) 2024-08-20 US claimed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 US claimed
US-20240173302-A1 TREATMENT OF INFLAMMATORY DISEASES DIMERIX BIOSCIENCE PTY LTD. (AU) 2024-05-30 US claimed
EP-4313024-A1 TREATMENT OF INFLAMMATORY DISEASES Dimerix Bioscience Pty Ltd (AU) 2024-02-07 EP claimed
US-11851443-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-12-26 US claimed
US-20230285340-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-09-14 US claimed
US-11718591-B2 Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-08-08 US claimed
WO-2023111196-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE SINGAPORE HEALTH SERVICES PTE. LTD. (SG) 2023-06-22 WO claimed
EP-1627638-A1 FORTIFIER TORAY INDUSTRIES, INC. (JP) 2006-02-22 EP claimed
WO-2006000564-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NEP-INHIBITORS, INHIBITORS OF THE ENDOGENOUS ENDOTHELIN PRODUCING SYSTEM AND AT1-RECEPTOR ANTAGONISTS SOLVAY PHARMACEUTICALS GMBH (DE) 2006-01-05 WO claimed
US-20050288272-A1 Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists SOLVAY PHARMACEUTICALS GMBH (DE) 2005-12-29 US claimed
EP-1545540-A2 COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2005-06-29 EP claimed
WO-2005023182-A2 NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-03-17 WO claimed
WO-2004080488-A2 COMBINED PREPARATIONS OF ACETYL SALICYLIC ACID WITH AN HMG-COA REDUCTASE INHIBITOR BAYER HEALTHCARE AG (DE) 2004-09-23 WO claimed
WO-2004017896-A2 COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 2004-03-04 WO claimed
EP-1258258-A1 Implantable device comprising a stent and angiotensin II receptor antagonists TERUMO KABUSHIKI KAISHA (JP) 2002-11-20 EP claimed
US-20020168393-A1 Implantable medical material and implantable medical device TERUMO KABUSHIKI KAISHA (JP) 2002-11-14 US claimed
WO-2000037075-A1 COMBINATION OF AN AT1 ANGIOTENSIN II RECEPTOR ANTAGONIST AND AN IMMUNOSUPPRESSANT SANOFI-SYNTHELABO (FR) 2000-06-29 WO claimed